225 related articles for article (PubMed ID: 24675715)
21. SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy.
Bettini S; Bordigato E; Milan G; Dal Pra' C; Favaretto F; Belligoli A; Sanna M; Serra R; Foletto M; Prevedello L; Busetto L; Fassina G; Vettor R; Fabris R
Obes Facts; 2019; 12(3):291-306. PubMed ID: 31104052
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
23. A targeted metabolomic profiling of plasma acylcarnitines in nonalcoholic fatty liver disease.
Chang Y; Gao XQ; Shen N; He J; Fan X; Chen K; Lin XH; Li HM; Tian FS; Li H
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7433-7441. PubMed ID: 32706083
[TBL] [Abstract][Full Text] [Related]
24. Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients.
Paredes-Turrubiarte G; González-Chávez A; Pérez-Tamayo R; Salazar-Vázquez BY; Hernández VS; Garibay-Nieto N; Fragoso JM; Escobedo G
Clin Exp Med; 2016 May; 16(2):193-202. PubMed ID: 25894568
[TBL] [Abstract][Full Text] [Related]
25. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease.
Sookoian S; Salatino A; Castaño GO; Landa MS; Fijalkowky C; Garaycoechea M; Pirola CJ
Gut; 2020 Aug; 69(8):1483-1491. PubMed ID: 31900291
[TBL] [Abstract][Full Text] [Related]
26. Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD).
Ajaz S; McPhail MJ; Gnudi L; Trovato FM; Mujib S; Napoli S; Carey I; Agarwal K
Mitochondrion; 2021 Mar; 57():119-130. PubMed ID: 33387664
[TBL] [Abstract][Full Text] [Related]
27. Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites.
von Schönfels W; Patsenker E; Fahrner R; Itzel T; Hinrichsen H; Brosch M; Erhart W; Gruodyte A; Vollnberg B; Richter K; Landrock A; Schreiber S; Brückner S; Beldi G; Sipos B; Becker T; Röcken C; Teufel A; Stickel F; Schafmayer C; Hampe J
Liver Int; 2015 Jan; 35(1):207-14. PubMed ID: 24484068
[TBL] [Abstract][Full Text] [Related]
28. Circulating microbiota-derived metabolites: a "liquid biopsy?
Aragonès G; Colom-Pellicer M; Aguilar C; Guiu-Jurado E; Martínez S; Sabench F; Antonio Porras J; Riesco D; Del Castillo D; Richart C; Auguet T
Int J Obes (Lond); 2020 Apr; 44(4):875-885. PubMed ID: 31388096
[TBL] [Abstract][Full Text] [Related]
29. Nonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: analysis of intraoperative liver biopsies and literature review.
Souto KP; Meinhardt NG; Ramos MJ; Ulbrich-Kulkzynski JM; Stein AT; Damin DC
Surg Obes Relat Dis; 2018 Jan; 14(1):66-73. PubMed ID: 29104004
[TBL] [Abstract][Full Text] [Related]
30. Detection of non-alcoholic steatohepatitis in patients with morbid obesity before bariatric surgery: preliminary evaluation with acoustic radiation force impulse imaging.
Guzmán-Aroca F; Frutos-Bernal MD; Bas A; Luján-Mompeán JA; Reus M; Berná-Serna Jde D; Parrilla P
Eur Radiol; 2012 Nov; 22(11):2525-32. PubMed ID: 22648049
[TBL] [Abstract][Full Text] [Related]
31. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.
Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS
Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365
[TBL] [Abstract][Full Text] [Related]
32. A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy.
Ramos-Molina B; Castellano-Castillo D; Pastor O; Ocaña-Wilhelmi L; Fernández-García D; Romero-Gómez M; Cardona F; Tinahones FJ
Obes Surg; 2019 Mar; 29(3):983-989. PubMed ID: 30488259
[TBL] [Abstract][Full Text] [Related]
33. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
Williams KH; Vieira De Ribeiro AJ; Prakoso E; Veillard AS; Shackel NA; Brooks B; Bu Y; Cavanagh E; Raleigh J; McLennan SV; McCaughan GW; Keane FM; Zekry A; Gorrell MD; Twigg SM
J Diabetes; 2015 Nov; 7(6):809-19. PubMed ID: 25350950
[TBL] [Abstract][Full Text] [Related]
34. Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery.
Yuan X; Chen J; Cheng Q; Zhao Y; Zhang P; Shao X; Bi Y; Shi X; Ding Y; Sun X; Xue B
BMC Gastroenterol; 2018 Oct; 18(1):147. PubMed ID: 30285651
[TBL] [Abstract][Full Text] [Related]
35. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
[TBL] [Abstract][Full Text] [Related]
36. The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: "NASHOST" prospective observational trial.
Praveen Raj P; Gomes RM; Kumar S; Senthilnathan P; Karthikeyan P; Shankar A; Palanivelu C
Surg Obes Relat Dis; 2015; 11(6):1315-22. PubMed ID: 26003897
[TBL] [Abstract][Full Text] [Related]
37. SFRP5 hepatic expression is associated with non-alcoholic liver disease in morbidly obese women.
Gutiérrez-Vidal R; Vega-Badillo J; Reyes-Fermín LM; Hernández-Pérez HA; Sánchez-Muñoz F; López-Álvarez GS; Larrieta-Carrasco E; Fernández-Silva I; Méndez-Sánchez N; Tovar AR; Villamil-Ramírez H; Mejía-Domínguez AM; Villarreal-Molina T; Hernández-Pando R; Campos-Pérez F; Aguilar-Salinas CA; Canizales-Quinteros S
Ann Hepatol; 2015; 14(5):666-74. PubMed ID: 26256895
[TBL] [Abstract][Full Text] [Related]
38. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
39. Rice endosperm protein slows progression of fatty liver and diabetic nephropathy in Zucker diabetic fatty rats.
Kubota M; Watanabe R; Yamaguchi M; Hosojima M; Saito A; Fujii M; Fujimura S; Kadowaki M
Br J Nutr; 2016 Oct; 116(8):1326-1335. PubMed ID: 27724997
[TBL] [Abstract][Full Text] [Related]
40. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
